June 15, 2015 / 8:32 PM / 4 years ago

Avalanche Biotech's eye drug meets main goal in mid-stage study

(Reuters) - Avalanche Biotechnologies Inc said its experimental eye drug met the main goal of a mid-stage study, sending its shares up about 16 percent after the bell.

The drug, AVA-101, was effective in improving vision, compared with a placebo, in patients with wet age-related macular degeneration (AMD) - a disease affecting the retina of the eye, the drug developer said in a statement on Monday.

Reporting by Rosmi Shaji in Bengaluru; Editing by Saumyadeb Chakrabarty

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below